OrbiMed

Activity in this selectionBiotech

By stage

Series A4

Series B3

Series C+3

Biotech10

United States7

Canada1

China1

Denmark1

10 in this selection

Aug 17

Develops neuro-metabolic therapeutics for schizophrenia and ALS

$30MSeries A

Role not disclosed

May 18

Develops novel therapeutics for immune mediated diseases

$50MSeries C

Role not disclosed

Apr 29

Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases

$50MSeries A+

Role not disclosed

Apr 15

Develops highly targeted, small molecule medicines for cancer and rare diseases

$108MSeries C

Role not disclosed

Apr 14

Develops first- and best-in-class antibody-drug conjugates (ADCs) for cancer treatment

$75MSeries C

Role not disclosed

Apr 8

Develops next-generation bispecific ADCs for cancer treatment

$137MSeries B

Role not disclosed